Research programme: antibacterials - Thallion Pharmaceuticals
Alternative Names: Antibacterials research programme - Thallion Pharmaceuticals; ECO 00501Latest Information Update: 25 Aug 2009
At a glance
- Originator Ecopia BioSciences
- Class Antibacterials
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 15 Nov 2004 Data presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2004) have been added to the Adverse events, pharmacokinetics and Viral Infections Antimicrobial Activity and pharmacodynamics section ,
- 16 Sep 2003 Preclinical trials in Bacterial infections in Canada (unspecified route)